GlassScriptPhysician profile
Samantha Jane Garber
NPI 1871284885
$2,733.80
in general payments reported to CMS, 2019-2025
19 companies · $758 in 2025
The $758 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $623 · 2024: $1,353 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.21 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $344.30 | 2024-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $305.70 | 2023-2025 | Loreev Xr, Gralise |
| Janssen Pharmaceuticals, INC | $238.84 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Tempus Ai, INC | $200.65 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $190.88 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $170.07 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $139.60 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.13 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $129.14 | 2023-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $97.22 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $88.51 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $81.59 | 2024 | Rexulti |
| Blue Earth Diagnostics | $79.84 | 2024 | |
| Corium, LLC | $67.69 | 2023-2024 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $55.08 | 2025 | Sublocade |
| Tris Pharma INC | $14.45 | 2024 | Onyda Xr |
| Axsome Therapeutics, INC. | $14.39 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $13.51 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.